Cancer is the second leading cause of death in the United States after heart disease[1], anticipated to cause 570,000 deaths in 2012 alone. The most common cancers in the United States are lung, skin, breast, prostate, and colon cancer[2]. There have been tremendous advances in pre-clinical and clinical development of molecularly targeted therapies for these common cancers such as inhibitors of the epidermal growth factor receptor (EGFR), BRAF kinase, ERBB2 gene amplification (HER2), and androgen signaling pathway5(3-5]. In contrast to common cancers, rare cancers such as sarcomas present a challenge to the clinical oncologist since there are typically few retrospective studies available and little known about the molecular underpinnings. Thus, this clinical tumor sequencing study focuses on patients with these rare cancers to 1) provide clinically significant genomic sequencing data to patients and their doctors, and 2) expand the molecular taxonomy of these poorly defined cancers.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1HG006508-03
Application #
8857144
Study Section
Special Emphasis Panel (ZHG1-HGR-N)
Project Start
Project End
2016-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
3
Fiscal Year
2015
Total Cost
$357,727
Indirect Cost
$126,936
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Roberts, J Scott; Robinson, Jill O; Diamond, Pamela M et al. (2018) Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project. Genet Med 20:1069-1076
Mankuzhy, Nikhil P; Walling, Emily; Anderson, Bailey et al. (2018) Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol :
Christensen, Kurt D; Bernhardt, Barbara A; Jarvik, Gail P et al. (2018) Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. Genet Med 20:1186-1195
Prasad, Rahul M; Mody, Rajen J; Myers, George et al. (2018) A genome-wide analysis of colorectal cancer in a child with Noonan syndrome. Pediatr Blood Cancer 65:e27362
Weipert, Caroline M; Ryan, Kerry A; Everett, Jessica N et al. (2018) Physician Experiences and Understanding of Genomic Sequencing in Oncology. J Genet Couns 27:187-196
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Spector-Bagdady, Kayte; Prince, Anya E R; Yu, Joon-Ho et al. (2018) Analysis of state laws on informed consent for clinical genetic testing in the era of genomic sequencing. Am J Med Genet C Semin Med Genet 178:81-88
Tran, Dustin; Camelo-Piragua, Sandra; Gupta, Avneesh et al. (2017) Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor. J Pediatr Hematol Oncol 39:e466-e469
Ryan, Kerry A; De Vries, Raymond G; Uhlmann, Wendy R et al. (2017) Public's Views toward Return of Secondary Results in Genomic Sequencing: It's (Almost) All about the Choice. J Genet Couns 26:1197-1212
Koschmann, Carl; Farooqui, Zishaan; Kasaian, Katayoon et al. (2017) Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. NPJ Precis Oncol 1:32

Showing the most recent 10 out of 52 publications